BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Systemic Sclerosis readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Systemic Sclerosis\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05925803-5367@assetmemo.bio
DTSTAMP:20261122T012610Z
DTSTART;VALUE=DATE:20270106
DTEND;VALUE=DATE:20270107
SUMMARY:Anifrolumab: Phase 3 readout est. (NCT05925803)
DESCRIPTION:Anifrolumab\, phase 3\, Systemic Sclerosis.\nStudy: Determine E
 ffectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)\nEstimated prima
 ry completion: 6 January 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/anifrolumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05925803
URL:https://assetmemo.bio/drug/anifrolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07748000-521@assetmemo.bio
DTSTAMP:20261122T012610Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Treprostinil (Yutrepia\, Liquidia): Phase 2 readout est. (NCT077480
 00)
DESCRIPTION:Treprostinil (Yutrepia\, Liquidia)\, phase 2\, Systemic Scleros
 is.\nStudy: A Study of LIQ861 (Inhaled Treprostinil) in Adults With System
 ic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks\nEstimated 
 primary completion: February 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/treprostinil-yutrepia-liquidia#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07748000
URL:https://assetmemo.bio/drug/treprostinil-yutrepia-liquidia#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06297096-1977@assetmemo.bio
DTSTAMP:20261122T012610Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Nintedanib (Ofev): Phase 3 readout est. (NCT06297096)
DESCRIPTION:Nintedanib (Ofev)\, phase 3\, Systemic Sclerosis.\nStudy: Study
  of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Scler
 osis and Interstitial Lung Disease\nEstimated primary completion: 30 Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nintedanib-
 ofev#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06297096
URL:https://assetmemo.bio/drug/nintedanib-ofev#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07335562-1977@assetmemo.bio
DTSTAMP:20261122T012610Z
DTSTART;VALUE=DATE:20281114
DTEND;VALUE=DATE:20281115
SUMMARY:Nintedanib (Ofev): Phase 3 readout est. (NCT07335562)
DESCRIPTION:Nintedanib (Ofev)\, phase 3\, Systemic Sclerosis.\nStudy: A Stu
 dy to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autole
 ucel / Zola-cel)\, CD19-CAR T Cells\, Versus Standard of Care in Participa
 nts With Active Systemic Sclerosis\nEstimated primary completion: 14 Novem
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nintedanib-
 ofev#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07335562
URL:https://assetmemo.bio/drug/nintedanib-ofev#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07497087-10645@assetmemo.bio
DTSTAMP:20261122T012610Z
DTSTART;VALUE=DATE:20300226
DTEND;VALUE=DATE:20300227
SUMMARY:Nerandomilast (Jascayd): Phase 3 readout est. (NCT07497087)
DESCRIPTION:Nerandomilast (Jascayd)\, phase 3\, Systemic Sclerosis.\nStudy:
  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosi
 s\nEstimated primary completion: 26 February 2030. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07497087
URL:https://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07691970-5367@assetmemo.bio
DTSTAMP:20261122T012610Z
DTSTART;VALUE=DATE:20321230
DTEND;VALUE=DATE:20321231
SUMMARY:Anifrolumab: Phase 3 readout est. (NCT07691970)
DESCRIPTION:Anifrolumab\, phase 3\, Systemic Lupus Erythematosus.\nStudy: R
 ollover Study for Participants Who Have Completed a Previous Clinical Stud
 y With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Trea
 tment\nEstimated primary completion: 30 December 2032. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/anifrolumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07691970
URL:https://assetmemo.bio/drug/anifrolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
